Business Standard

Wednesday, December 25, 2024 | 01:05 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Biocon gains 5% as two Bengaluru facilities receive EIR from USFDA

The stock was trading close to its all-time high level of Rs 359, touched in September 2018

Biocon
Premium

Biocon

SI Reporter Mumbai
Shares of Biocon jumped 5 per cent to Rs 353 on the BSE on Thursday after the company’s biologics manufacturing facilities in Bengaluru received the Establishment Inspection Report (EIR) from the US health regulator.

The stock was trading close to its all-time high level of Rs 359, touched in September 2018.

“Biocon Biologics India, a subsidiary of Biocon, has received the EIR from the US Food and Drug Administration (USFDA) for the Pre-Approval Inspection (PAI) at two of its biologics manufacturing facilities in Bengaluru,” the company said in an exchange filing.

The inspection was conducted between September

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in